ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1652

Basement Membrane Remodeling Is Significantly Increased with Rheumatoid Arthritis and Suppressed By IL6 Inhibition: Analysis of Two Phase III Clinical Trial

Natasja Stæhr Gudman1, Pernille Juhl2, Christian S. Thudium3, Anne Sofie Siebuhr4, Inger Byrjalsen5, Morten Asser Karsdal4 and Anne C. Bay-Jensen4, 1Nordic Bioscience A/S, Herlev, Denmark, 2Biomarkers & Research, Nordic Bioscience, Herlev, Denmark, 3Biomarkers and Research, Nordic Bioscience, Herlev, Denmark, 4Rheumatology, Nordic Bioscience, Herlev, Denmark, 5Nordic Bioscience, Clinical Development, Herlev, Denmark

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: Biomarkers, Collagen, endothelial cells and rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 14, 2016

Title: Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy - Poster II

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Rheumatoid arthritis (RA) is associated with neovascularization of the synovial membrane and increased risk of cardiovascular disease, consequent to vascular and endothelial dysfunction, which leads to remodeling, and degradation of the basement membrane proteins, such as type IV collagen. The purpose of the study was to investigate the association between basement membrane turnover and disease activity, as well as structural progression in RA.

Methods: Serum samples from patients giving informed consent of the LITHE (n=740) and RADIATE (n=217) studies (two phase III double-blinded placebo controlled studies testing 4- and 8-mg/kg tocilizumab (TCZ) in combination with methotrexate) were included. Basement membrane turnover was measured by the blood-based biomarker C4M reflecting MMP-degraded type IV collagen degradation at baseline, week 4, 16, 24 and 52, and at baseline and week 16 in the LITHE and the RADIATE study. Associations between basement membrane turnovers, treatment response and clinical parameters.

Results:  Basement membrane turnover was associated with clinical scores including visual analog scale for pain (p<0.0001) and DAS28 DAS28 (p=<0.0001) in both studies (table). It was dose-dependently reduced by TCZ (11-40%, figure) and baseline levels were significantly correlated with change in radiographic scores (joint space narrowing (p=0.001) and sharp score (p=0.0002)).    

Conclusion: Basement membrane remodeling was associated with disease activity and radiographic progression at baseline, and was dose-dependently inhibited by TCZ, suggesting a continuous clinical benefit extending past the joint tissue. These data suggest that active RA and disease progression is associated with increased remodeling of basement membrane collagen.

 

table   LITHE   RADIATE
  r p r P
Age, years   ns   ns
Gender, Male %   ns   ns
BMI   ns   ns
Disease duration, mean years (95%-CI)   ns   ns
Baseline CRP, mg/dl 0.64 <0.0001 0.58 <0.0001
HAQ 0.24 <0.0001 0.30 0.0025
VAS pain 0.21 <0.0001 0.32 <0.0001
DAS28 0.30 <0.0001 0.32 <0.0001
JSN 0.14 0.0002 NA –
SHP 0.14 0.0002 NA –
ERN 0.14 0.002 NA –

Figure 1. C4M levels were suppressed by IL-6R. A) Showing percentage change from baseline to week 4, 16, 24 and 54 for each of the 3 treatment groups in LITHE. B) Suppression of C4M in LITHE week 16. C) Suppression of C4M in RADIATE week 16. Error bars are shown as SEM. Significant levels are depicted *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001.  


Disclosure: N. S. Gudman, Nordic Bioscience A/S, 3; P. Juhl, Nordic Bioscience Diagnostic, 3; C. S. Thudium, Nordic Bioscience A/S, 3; A. S. Siebuhr, Nordic Bioscience Diagnostic, 3; I. Byrjalsen, Nordic Bioscience A/S, 3; M. A. Karsdal, Nordic Bioscience A/S, 1,Nordic Bioscience A/S, 3; A. C. Bay-Jensen, Nordic Bioscience A/, 1,Nordic Bioscience A/S, 3,D-BOARD, 2.

To cite this abstract in AMA style:

Gudman NS, Juhl P, Thudium CS, Siebuhr AS, Byrjalsen I, Karsdal MA, Bay-Jensen AC. Basement Membrane Remodeling Is Significantly Increased with Rheumatoid Arthritis and Suppressed By IL6 Inhibition: Analysis of Two Phase III Clinical Trial [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/basement-membrane-remodeling-is-significantly-increased-with-rheumatoid-arthritis-and-suppressed-by-il6-inhibition-analysis-of-two-phase-iii-clinical-trial/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/basement-membrane-remodeling-is-significantly-increased-with-rheumatoid-arthritis-and-suppressed-by-il6-inhibition-analysis-of-two-phase-iii-clinical-trial/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology